Immutep (ASX:IMM) posts 30.9-month survival as TACTI-004 forensics finally get interesting

INSIGHT-003 keeps beating the 22-month benchmark while immune profile data hints at what went wrong

Immutep (ASX:IMM) has delivered the kind of split-screen update that biotech investors have to read twice. On one side, the small INSIGHT-003 Phase 1 trial in first-line non-small cell lung cancer just posted a mature median overall survival of 30.9 months. On the other, the company is still forensically pulling apart why the much larger TACTI-004 Phase 3 failed earlier this year.

The 30.9-month number matters because roughly 92% of patients in INSIGHT-003 had low or no PD-L1 expression, the harder-to-treat majority of NSCLC cases. The historical benchmark from the KEYNOTE-189 trial of Keytruda plus chemotherapy sits at 22.0 months in a broader population. So efti plus Keytruda plus chemo is running roughly nine months ahead of standard of care in a sicker patient mix.

The TACTI-004 failure in March remains the elephant in the room. Management now thinks something specific and identifiable went wrong in that Phase 3, and the immune monitoring data may be pointing at it.

The INSIGHT-003 survival curve keeps holding up

Mature data is worth more than early data, and INSIGHT-003 now has a minimum 30 months of follow-up. Overall survival of 30.9 months in the full 51-patient cohort, and the same 30.9 months in the 47-patient low-PD-L1 subgroup, is a genuinely strong signal in a population that typically responds poorly to PD-1 based therapy.

The objective response rate in INSIGHT-003 has held at 62.7%, in line with the ESMO 2025 readout. In the failed TACTI-004 trial, the efti arm posted 42.9% ORR versus 55.1% for placebo plus standard of care. That gap between the two studies is the puzzle management is trying to solve.

The immune profile clue is the real news buried in this release

The genuinely new information today sits in one paragraph on the root cause work. Preliminary immune monitoring from TACTI-004 shows a markedly different immune activation profile compared with almost 600 patients dosed across five prior efti studies, and different again from INSIGHT-003.

In plain English, patients on TACTI-004 do not appear to have responded to efti the way patients in every previous trial did. That points away from the biology of the drug and towards something about how it was made or administered in this specific Phase 3. Immutep has flagged manufacturing as one factor under review, with Dr Reddy’s and WuXi Biologics assisting.

We think this is the single most important line in the release. If the root cause turns out to be a manufacturing issue rather than a drug failure, the whole efti program looks different.

What still cannot be dressed up

The skeptical read is that a mature Phase 1 result of 51 patients cannot un-do a failed Phase 3 of 173 patients at interim. The Phase 3 read out negative on both squamous and non-squamous cohorts, and across every PD-L1 subgroup.

The path forward for efti in first-line NSCLC now requires either a convincing root cause explanation that isolates the failure, or a new trial design, or both. Neither is quick, and neither is cheap.

The Investors Takeaway for Immutep

The bull case rebuild rests on Q3 CY2026. If the root cause analysis identifies a specific, correctable reason TACTI-004 underperformed, and the immune profile data supports that story, efti moves back into the NSCLC conversation. The 30.9-month INSIGHT-003 survival number gives that argument something concrete to stand on.

If Q3 comes and goes without a clear explanation, the market will treat efti’s NSCLC ambitions as effectively over, and value the company on its sarcoma and head and neck programs alone. Our prior coverage at stocksdownunder walked through the post-Phase 3 rebuild, and today’s update is the next real test of whether that rebuild has legs.